<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="43510">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01860625</url>
  </required_header>
  <id_info>
    <org_study_id>IPI-001</org_study_id>
    <nct_id>NCT01860625</nct_id>
  </id_info>
  <brief_title>A Phase I Clinical, Dose Escalation Study of the Safety, Tolerability and Pharmacokinetics of Donepezil Patch in Healthy Male Subjects</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Icure Pharmaceutical Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Icure Pharmaceutical Inc.</source>
  <oversight_info>
    <authority>South Korea: Ministry of Food and Drug Safety</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study of the Safety, tolerability and pharmacokinetics with single dose of donepezil patch
      in healthy male subjects.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">February 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>safety and tolerability evaluation</measure>
    <time_frame>-1d~20d</time_frame>
    <safety_issue>No</safety_issue>
    <description>evaluation item
adverse event
electrocardiographie
vital sign
physical examination
urine, blood test
skin irritation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>pharmacokinetics characteristic evaluation</measure>
    <time_frame>1d 0h(before administration), (after administration)4h, 8h, 12h, 24h, 48h, 70h, 72h, 74h, 76h, 80h, 96h, 120h, 144h, 168h, 216h, 264h, 312h</time_frame>
    <safety_issue>No</safety_issue>
    <description>evaluation item : donepezil conc.
evaluation variable
AUC last, AUC0-∞, Cmax, tmax, t1/2β, CL/F</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>1(12.5㎠)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>drug : 9 people, 43.75mg/12.5㎠
placebo : 3 people, 12.5㎠</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2(25㎠)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>drug : 9 people, 87.5mg/25㎠
placebo : 3 people, 25㎠</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3(50㎠)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>drug : 9 people, 175mg/50㎠
placebo : 3 people, 50㎠</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Donepezil patch</intervention_name>
    <arm_group_label>1(12.5㎠)</arm_group_label>
    <arm_group_label>2(25㎠)</arm_group_label>
    <arm_group_label>3(50㎠)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>1(12.5㎠)</arm_group_label>
    <arm_group_label>2(25㎠)</arm_group_label>
    <arm_group_label>3(50㎠)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI : more than 20 ㎏/㎡, less than 26 ㎏/㎡

          -  Systolic blood pressure : more than 90, less than 140 (mmHg)

          -  Diastolic blood pressure : more than 60, less than 100 (mmHg)

        Exclusion Criteria:

          -  Evidence of clinically significant, severe, active, or unstable gastrointestinal,
             renal,hepatic, respiratory, hematological, endocrine, or cardiovascular system
             disease.

          -  A history of skin disease or skin graft

          -  Hypersensitivity to donepezil or piperidine derivatives or any of the excipients.

          -  A known or suspected history of drug or alcohol dependency or abuse

          -  Patients who have participated in another clinical study within 60 days.

          -  Whole blood within 60 days, apheresis within 30 days, transfusion within 30 days

          -  Heavy caffeine intake(more than 5 units/day)

          -  Heavy alcohol intake(more than 21 units/week)

          -  Heavy smoker(more than 10 cigarette/day)

          -  Abnormal clinical laboratory values which are judged clinically significant by the
             investigator.

          -  Any condition that would make the patient or the caregiver, in the opinion of the
             investigator, unsuitable for the study.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>ASAN Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <lastchanged_date>May 22, 2013</lastchanged_date>
  <firstreceived_date>May 15, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Donepezil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
